CD274/PDCD1LG2 (PD-L1/PD-L2) gains, amplifications, and translocations are another mechanism by which DLBCL evades destruction by T cells, because binding of this ligand to PD-1 receptors on CD8+/CD4+ T cells prevents activation (Georgiou et al., 2016). Here, CD8A is linked to diffuse large B-cell lymphoma.